Literature DB >> 11226154

The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1.

F Maingret1, A J Patel, M Lazdunski, E Honoré.   

Abstract

TASK-1 encodes an acid- and anaesthetic-sensitive background K(+) current, which sets the resting membrane potential of both cerebellar granule neurons and somatic motoneurons. We demonstrate that TASK-1, unlike the other two pore (2P) domain K(+) channels, is directly blocked by submicromolar concentrations of the endocannabinoid anandamide, independently of the CB1 and CB2 receptors. In cerebellar granule neurons, anandamide also blocks the TASK-1 standing-outward K(+) current, IKso, and induces depolarization. Anandamide-induced neurobehavioural effects are only partly reversed by antagonists of the cannabinoid receptors, suggesting the involvement of alternative pathways. TASK-1 constitutes a novel sensitive molecular target for this endocannabinoid.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226154      PMCID: PMC140203          DOI: 10.1093/emboj/20.1.47

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  47 in total

1.  TASK-3, a novel tandem pore domain acid-sensitive K+ channel. An extracellular histiding as pH sensor.

Authors:  S Rajan; E Wischmeyer; G Xin Liu; R Preisig-Müller; J Daut; A Karschin; C Derst
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

Review 2.  Potassium-channel closure taken to TASK.

Authors:  R A North
Journal:  Trends Neurosci       Date:  2000-06       Impact factor: 13.837

Review 3.  Neurobiology: the acid test for resting potassium channels.

Authors:  D A Brown
Journal:  Curr Biol       Date:  2000-06-15       Impact factor: 10.834

4.  The TASK-1 two-pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics.

Authors:  J E Sirois; Q Lei; E M Talley; C Lynch; D A Bayliss
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

5.  Background K+ channels: an important target for volatile anesthetics?

Authors:  N P Franks; W R Lieb
Journal:  Nat Neurosci       Date:  1999-05       Impact factor: 24.884

6.  TREK-2, a new member of the mechanosensitive tandem-pore K+ channel family.

Authors:  H Bang; Y Kim; D Kim
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

7.  Cloning of a new mouse two-P domain channel subunit and a human homologue with a unique pore structure.

Authors:  M Salinas; R Reyes; F Lesage; M Fosset; C Heurteaux; G Romey; M Lazdunski
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

8.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide.

Authors:  P M Zygmunt; J Petersson; D A Andersson; H Chuang; M Sørgård; V Di Marzo; D Julius; E D Högestätt
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

9.  TASK (TWIK-related acid-sensitive K+ channel) is expressed in glomerulosa cells of rat adrenal cortex and inhibited by angiotensin II.

Authors:  G Czirják; T Fischer; A Spät; F Lesage; P Enyedi
Journal:  Mol Endocrinol       Date:  2000-06

10.  An oxygen-, acid- and anaesthetic-sensitive TASK-like background potassium channel in rat arterial chemoreceptor cells.

Authors:  K J Buckler; B A Williams; E Honore
Journal:  J Physiol       Date:  2000-05-15       Impact factor: 5.182

View more
  98 in total

1.  Interaction with 14-3-3 proteins promotes functional expression of the potassium channels TASK-1 and TASK-3.

Authors:  Sindhu Rajan; Regina Preisig-Müller; Erhard Wischmeyer; Ralf Nehring; Peter J Hanley; Vijay Renigunta; Boris Musset; Günter Schlichthörl; Christian Derst; Andreas Karschin; Jürgen Daut
Journal:  J Physiol       Date:  2002-11-15       Impact factor: 5.182

Review 2.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

3.  Mechanisms underlying excitatory effects of group I metabotropic glutamate receptors via inhibition of 2P domain K+ channels.

Authors:  Jean Chemin; Christophe Girard; Fabrice Duprat; Florian Lesage; Georges Romey; Michel Lazdunski
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

Review 4.  Emerging roles for endocannabinoids in long-term synaptic plasticity.

Authors:  Gregory L Gerdeman; David M Lovinger
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

Review 5.  The complexities of the cardiovascular actions of cannabinoids.

Authors:  Michael D Randall; David A Kendall; Saoirse O'Sullivan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

Review 6.  The 2P-domain K+ channels: role in apoptosis and tumorigenesis.

Authors:  Amanda J Patel; Michel Lazdunski
Journal:  Pflugers Arch       Date:  2004-05-05       Impact factor: 3.657

7.  Selective block of the human 2-P domain potassium channel, TASK-3, and the native leak potassium current, IKSO, by zinc.

Authors:  Catherine E Clarke; Emma L Veale; Paula J Green; Helen J Meadows; Alistair Mathie
Journal:  J Physiol       Date:  2004-07-29       Impact factor: 5.182

8.  TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation.

Authors:  C Seyler; E Duthil-Straub; E Zitron; J Gierten; E P Scholz; R H A Fink; C A Karle; R Becker; H A Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

9.  Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex.

Authors:  Grzegorz Godlewski; Manfred Göthert; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

10.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Authors:  T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.